The telehealth provider Hims & Hers finds itself navigating a pivotal moment. As the company launches a key service in the United Kingdom, a proposed piece of legislation in the United States threatens to undermine a highly profitable segment of its domestic business. Shares closed Friday’s session at $37.24, showing little change from the prior day. This surface calm, however, belies significant underlying tensions concerning the firm’s future direction.

Investor sentiment was rattled earlier in the week when shares dropped approximately 4.4% following the introduction of the „SAFE Drugs Act of 2025.“ This legislative proposal takes direct aim at the compounding of GLP-1 medications, a practice that has become a major growth engine for Hims & Hers. Should the act pass into law, the company could be forced to pivot to sourcing brand-name drugs. Such a shift would present a dual challenge: branded pharmaceuticals carry significantly lower profit margins and are currently facing severe supply shortages.

The outcome presents a binary scenario for the business. If the legislative effort fails or is significantly diluted, Hims & Hers can continue to capitalize on the supply constraints affecting branded drugs. A strict enforcement of the proposed rules, conversely, would necessitate a fundamental restructuring of its operational model.

Strategic International Expansion Provides a Counterbalance

In a strategic move to diversify its geographic reliance, the company this week introduced its „Hers“ platform in the United Kingdom. The offering features a comprehensive weight management program, providing access to GLP-1 medications like Wegovy and Mounjaro alongside oral treatments. This launch builds upon the company’s existing UK portfolio for men’s health, skincare, and hair loss solutions.


Should investors sell immediately? Or is it worth buying Hims & Hers?

This international push follows the acquisition of the European telehealth platform Zava earlier this year. The expansion is widely viewed as a deliberate effort to establish a substantial operational base outside the U.S., a move that appears prescient given the current regulatory climate in Washington.

Insider Transaction Draws Market Scrutiny

Amid this period of uncertainty, a transaction by a company director has attracted attention. Andrea G. Perez Garcia sold 2,500 shares this week. While such sales can be motivated by a variety of personal financial reasons, they are often scrutinized more closely during times of regulatory ambiguity. Market observers are likely to monitor whether other executives follow suit.

The technical stabilization of the stock price on Friday suggests the initial wave of selling pressure following the legislative announcement may have subsided. Investors are now weighing two opposing forces: the potential of international growth against mounting regulatory risk in the company’s home market. Hims & Hers is scheduled to report quarterly earnings on January 31, 2025. This update may offer crucial insight into whether early UK revenue can begin to offset the potential headwinds developing stateside.

Ad

Hims & Hers Stock: Buy or Sell?! New Hims & Hers Analysis from December 13 delivers the answer:

The latest Hims & Hers figures speak for themselves: Urgent action needed for Hims & Hers investors.
Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 13.

Hims & Hers: Buy or sell?

Read more here…